Gilead Sciences Trading Volume Drops 67.69% to 75th Position Despite Strong Buy Rating

On March 24, 2025, Gilead Sciences (GILD) experienced a decline of 0.32%, with a trading volume of 9.14 billion, marking a 67.69% decrease from the previous day. This placed Gilead at the 75th position in terms of trading volume for the day.

Gilead Sciences has received a strong buy rating from analysts despite concerns over budget cuts and upcoming catalysts. Michael Yee from Jefferies maintained a buy rating on Gilead, highlighting the company's potential despite market uncertainties.

Gilead Sciences has been actively involved in expanding its HIV treatment options. The company presented new HIV treatment and cure research data at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025, including an investigational long-acting, twice-yearly therapy option. This development is part of Gilead's ongoing efforts to advance HIV prevention and treatment.

Gilead Sciences has also been impacted by reports of potential cuts in HIV prevention spending by the Trump administration. This news has led to a decline in the company's stock price, as investors weigh the potential impact on Gilead's revenue and market position. Despite this, some analysts remain optimistic about Gilead's long-term prospects, citing the company's strong portfolio of HIV treatments and its ongoing research and development efforts.